These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 17106924)
1. Inhibition of hepatic tumor cell proliferation in vitro and tumor growth in vivo by taltobulin, a synthetic analogue of the tripeptide hemiasterlin. Vashist YK; Tiffon C; Stoupis C; Redaelli CA World J Gastroenterol; 2006 Nov; 12(42):6771-8. PubMed ID: 17106924 [TBL] [Abstract][Full Text] [Related]
2. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Loganzo F; Discafani CM; Annable T; Beyer C; Musto S; Hari M; Tan X; Hardy C; Hernandez R; Baxter M; Singanallore T; Khafizova G; Poruchynsky MS; Fojo T; Nieman JA; Ayral-Kaloustian S; Zask A; Andersen RJ; Greenberger LM Cancer Res; 2003 Apr; 63(8):1838-45. PubMed ID: 12702571 [TBL] [Abstract][Full Text] [Related]
3. Intravesical chemotherapy of high-grade bladder cancer with HTI-286, a synthetic analogue of the marine sponge product hemiasterlin. Hadaschik BA; Adomat H; Fazli L; Fradet Y; Andersen RJ; Gleave ME; So AI Clin Cancer Res; 2008 Mar; 14(5):1510-8. PubMed ID: 18316576 [TBL] [Abstract][Full Text] [Related]
4. Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin. Hadaschik BA; Ettinger S; Sowery RD; Zoubeidi A; Andersen RJ; Roberge M; Gleave ME Int J Cancer; 2008 May; 122(10):2368-76. PubMed ID: 18240145 [TBL] [Abstract][Full Text] [Related]
5. Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability. Poruchynsky MS; Kim JH; Nogales E; Annable T; Loganzo F; Greenberger LM; Sackett DL; Fojo T Biochemistry; 2004 Nov; 43(44):13944-54. PubMed ID: 15518543 [TBL] [Abstract][Full Text] [Related]
6. Hybrids of the hemiasterlin analogue taltobulin and the dolastatins are potent antimicrotubule agents. Zask A; Kaplan J; Musto S; Loganzo F J Am Chem Soc; 2005 Dec; 127(50):17667-71. PubMed ID: 16351096 [TBL] [Abstract][Full Text] [Related]
7. Biophysical characterization of the interactions of HTI-286 with tubulin heterodimer and microtubules. Krishnamurthy G; Cheng W; Lo MC; Aulabaugh A; Razinkov V; Ding W; Loganzo F; Zask A; Ellestad G Biochemistry; 2003 Nov; 42(46):13484-95. PubMed ID: 14621994 [TBL] [Abstract][Full Text] [Related]
8. Expeditious Total Synthesis of Hemiasterlin through a Convergent Multicomponent Strategy and Its Use in Targeted Cancer Therapeutics. Charoenpattarapreeda J; Walsh SJ; Carroll JS; Spring DR Angew Chem Int Ed Engl; 2020 Dec; 59(51):23045-23050. PubMed ID: 32894646 [TBL] [Abstract][Full Text] [Related]
9. YSL-12, a novel microtubule-destabilizing agent, exerts potent anti-tumor activity against colon cancer in vitro and in vivo. Cai D; Qiu Z; Yao W; Liu Y; Huang H; Liao S; Luo Q; Xie L; Lin Z Cancer Chemother Pharmacol; 2016 Jun; 77(6):1217-29. PubMed ID: 27107592 [TBL] [Abstract][Full Text] [Related]
10. A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer. Ahn S; Hwang DJ; Barrett CM; Yang J; Duke CB; Miller DD; Dalton JT Cancer Chemother Pharmacol; 2011 Feb; 67(2):293-304. PubMed ID: 20383708 [TBL] [Abstract][Full Text] [Related]
12. Two photoaffinity analogues of the tripeptide, hemiasterlin, exclusively label alpha-tubulin. Nunes M; Kaplan J; Wooters J; Hari M; Minnick AA; May MK; Shi C; Musto S; Beyer C; Krishnamurthy G; Qiu Y; Loganzo F; Ayral-Kaloustian S; Zask A; Greenberger LM Biochemistry; 2005 May; 44(18):6844-57. PubMed ID: 15865430 [TBL] [Abstract][Full Text] [Related]
13. Absolute configurations of tubulin inhibitors taltobulin (HTI-286) and HTI-042 characterized by X-ray diffraction analysis and NMR studies. Niu C; Ho DM; Williamson RT; Zask A; Ayral-Kaloustian S Bioorg Med Chem Lett; 2010 Mar; 20(5):1535-8. PubMed ID: 20137930 [TBL] [Abstract][Full Text] [Related]
14. XN05, a novel synthesized microtubule inhibitor, exhibits potent activity against human carcinoma cells in vitro. Wu R; Ding W; Liu T; Zhu H; Hu Y; Yang B; He Q Cancer Lett; 2009 Nov; 285(1):13-22. PubMed ID: 19647933 [TBL] [Abstract][Full Text] [Related]
15. D-piece modifications of the hemiasterlin analog HTI-286 produce potent tubulin inhibitors. Zask A; Birnberg G; Cheung K; Kaplan J; Niu C; Norton E; Yamashita A; Beyer C; Krishnamurthy G; Greenberger LM; Loganzo F; Ayral-Kaloustian S Bioorg Med Chem Lett; 2004 Aug; 14(16):4353-8. PubMed ID: 15261301 [TBL] [Abstract][Full Text] [Related]
16. Probing the interaction of HTI-286 with tubulin using a stilbene analogue. Lo MC; Aulabaugh A; Krishnamurthy G; Kaplan J; Zask A; Smith RP; Ellestad G J Am Chem Soc; 2004 Aug; 126(32):9898-9. PubMed ID: 15303845 [TBL] [Abstract][Full Text] [Related]
17. [Evaluation of the inhibitory effect of tripeptide tyroservatide on growth of human hepatocellular carcinoma using a hollow fiber assay]. Shi LX; Lu R; Wang L; Zhou CL; Xu Q; Zhu ZF; Ma R; Zhang HL; Jia J; Fu Z; Yao Z Zhonghua Zhong Liu Za Zhi; 2008 Oct; 30(10):725-8. PubMed ID: 19173797 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and activity of novel analogs of hemiasterlin as inhibitors of tubulin polymerization: modification of the A segment. Yamashita A; Norton EB; Kaplan JA; Niu C; Loganzo F; Hernandez R; Beyer CF; Annable T; Musto S; Discafani C; Zask A; Ayral-Kaloustian S Bioorg Med Chem Lett; 2004 Nov; 14(21):5317-22. PubMed ID: 15454219 [TBL] [Abstract][Full Text] [Related]
19. 2-Methoxyestradiol inhibits hepatocellular carcinoma cell growth by inhibiting Cdc25 and inducing cell cycle arrest and apoptosis. Kar S; Wang M; Carr BI Cancer Chemother Pharmacol; 2008 Oct; 62(5):831-40. PubMed ID: 18246350 [TBL] [Abstract][Full Text] [Related]